{"id":"https://openalex.org/W3096854740","doi":"https://doi.org/10.1182/blood-2020-134041","title":"Novel CAR T Modules (Tmod) to Target HLA-Class I Loss in Lymphoma","display_name":"Novel CAR T Modules (Tmod) to Target HLA-Class I Loss in Lymphoma","publication_year":2020,"publication_date":"2020-11-05","ids":{"openalex":"https://openalex.org/W3096854740","doi":"https://doi.org/10.1182/blood-2020-134041","mag":"3096854740"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-134041","doi":"https://doi.org/10.1182/blood-2020-134041","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134041","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031725051","display_name":"Agnes E. Hamburger","orcid":"https://orcid.org/0000-0002-2679-3673","observed_orcids":["https://orcid.org/0000-0002-2679-3673"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Agnes E. Hamburger","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066527544","display_name":"Breanna DiAndreth","orcid":"https://orcid.org/0000-0002-0302-6834","observed_orcids":["https://orcid.org/0000-0002-0302-6834"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Breanna DiAndreth","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051053006","display_name":"Mark E. Daris","orcid":"https://orcid.org/0000-0002-3879-8375","observed_orcids":["https://orcid.org/0000-0002-3879-8375"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark E. Daris","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001304812","display_name":"Melanie L. Munguia","orcid":"https://orcid.org/0009-0004-7021-7392","observed_orcids":["https://orcid.org/0009-0004-7021-7392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melanie L. Munguia","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kiran Deshmukh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kiran Deshmukh","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087923471","display_name":"Jee\u2010Young Mock","orcid":"https://orcid.org/0000-0002-4656-3357","observed_orcids":["https://orcid.org/0000-0002-4656-3357"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jee-Young Mock","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055379755","display_name":"Grace E. Asuelime","orcid":"https://orcid.org/0000-0002-7751-8014","observed_orcids":["https://orcid.org/0000-0002-7751-8014"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Grace E. Asuelime","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083150372","display_name":"Emily D. Lim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emily D. Lim","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057902360","display_name":"Michelle R. Kreke","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michelle R. Kreke","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048332817","display_name":"Talar Tokatlian","orcid":"https://orcid.org/0000-0002-1498-4245","observed_orcids":["https://orcid.org/0000-0002-1498-4245"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Talar Tokatlian","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016684714","display_name":"David G. Maloney","orcid":"https://orcid.org/0000-0002-8477-6919","observed_orcids":["https://orcid.org/0000-0002-8477-6919"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Maloney","raw_affiliation_strings":["Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110647399","display_name":"William Y. Go","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Y. Go","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053252660","display_name":"Alexander Kamb","orcid":"https://orcid.org/0000-0002-8675-6620","observed_orcids":["https://orcid.org/0000-0002-8675-6620"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexander Kamb","raw_affiliation_strings":["A2 Biotherapeutics, Agoura Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A2 Biotherapeutics, Agoura Hills, CA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.16057226,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"23","last_page":"24"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.8650000095367432},{"id":"https://openalex.org/keywords/hla-a-02","display_name":"HLA-A*02","score":0.8730000257492065},{"id":"https://openalex.org/keywords/t-cell-engineering","display_name":"T cell engineering","score":0.44699999690055847},{"id":"https://openalex.org/keywords/inhibitory-receptors","display_name":"inhibitory receptors","score":0.7490000128746033},{"id":"https://openalex.org/keywords/lymphoma","display_name":"lymphoma","score":0.6169999837875366},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.8299999833106995},{"id":"https://openalex.org/keywords/b-cell-aplasia","display_name":"B-cell aplasia","score":0.5320000052452087},{"id":"https://openalex.org/keywords/primary-t-cells","display_name":"primary T cells","score":0.5350000262260437},{"id":"https://openalex.org/keywords/raji-cells","display_name":"Raji cells","score":0.6069999933242798},{"id":"https://openalex.org/keywords/adoptive-cell-transfer","display_name":"adoptive cell transfer","score":0.6380000114440918},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.492000013589859}],"concepts":[{"id":"https://openalex.org/C16232356","wikidata":"https://www.wikidata.org/wiki/Q4215980","display_name":"Raji cell","level":3,"score":0.7044224739074707},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.657653272151947},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5493993163108826},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5190497040748596},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5029205679893494},{"id":"https://openalex.org/C188280979","wikidata":"https://www.wikidata.org/wiki/Q911125","display_name":"Human leukocyte antigen","level":3,"score":0.4782770574092865},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.4734872281551361},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.40878787636756897},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.37137752771377563},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.35860002040863037},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.15241944789886475}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-134041","doi":"https://doi.org/10.1182/blood-2020-134041","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134041","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3103313089","https://openalex.org/W4282914675","https://openalex.org/W4388047624","https://openalex.org/W4308376690","https://openalex.org/W4286294428","https://openalex.org/W3091221120","https://openalex.org/W7162663919","https://openalex.org/W4388085848","https://openalex.org/W3213505088","https://openalex.org/W3138655421"],"abstract_inverted_index":{"Background:":[0],"Chimeric":[1],"Antigen":[2],"Receptor":[3],"(CAR)":[4],"T-cell":[5,33,115,435],"therapy":[6,436],"is":[7,15,437],"a":[8,104,175,202,208,214,221,338,513,617,696,717],"proven,":[9],"powerful":[10,514],"clinical":[11,501],"modality.":[12],"However,":[13],"it":[14,497],"still":[16],"limited":[17],"by":[18,184,248],"the":[19,80,89,94,152,236,256,349,370,446,500,623,702,723],"fundamental":[20],"obstacle":[21],"of":[22,53,61,270,281,297,306,340,443,742],"cancer":[23,26,81],"therapy:":[24],"discriminating":[25],"from":[27,82,337,480],"normal":[28,36,83],"cells.":[29,84,149,313,484],"Current":[30,531,533,541,545,547,555,557,565,569,571,579,581,589,591,599,601,608,629,631,640,677,679,686,707,729,731],"FDA-approved":[31],"CAR":[32,111,197,229,262,311,318,332,364,380,390,403,434,456,488,505,508],"therapies":[34],"eliminate":[35],"B":[37,42,257,495],"cells,":[38,155,496],"leaving":[39],"patients":[40],"with":[41,100,274,303,416,523],"cell":[43,199,289],"aplasia,":[44],"hypogammaglobulinemia,":[45],"and":[46,65,78,128,213,253,286,293,301,325,345,408,419,426,441,448,474,482,520],"susceptible":[47],"to":[48,117,173,180,234,343,356,438,516],"infection.":[49],"HLA-Class":[50,524],"I":[51,525],"loss":[52],"heterozygosity":[54],"(LOH)":[55],"occurs":[56],"at":[57,88],"an":[58,739],"average":[59],"frequency":[60],"~13%":[62,67],"among":[63],"cancers":[64],"specifically":[66],"in":[68,98,122,126,129,278,374,398,424,427,445,536,550,560,574,584,594,604,611,616,622,634,643,682,689,695,701,710,716,722,734],"DLBCL":[69],"(Broad":[70],"Institute":[71],"TCGA":[72],"database).":[73],"These":[74],"losses":[75],"are":[76],"irreversible":[77],"distinguish":[79],"To":[85,133,150],"exploit":[86],"LOH":[87,121],"HLA":[90],"locus,":[91],"we":[92,143,156],"target":[93,118,493],"remaining":[95],"allelic":[96],"product":[97],"tumors":[99,522],"LOH.":[101,526],"We":[102,166],"evaluated":[103,266],"novel":[105,222],"AND":[106],"NOT":[107],"Boolean":[108],"logic":[109],"gate":[110],"T":[112,171,198,230,240,263,312,319,333,365,381,391,404,457,489,509],"module":[113,206,219,250],"(Tmod)":[114],"system":[116,515],"HLA-A*02":[119],"(A2)":[120],"lymphoma":[123,147,186,413],"using":[124,207,220],"both":[125,201,283,423],"vitro":[127,260,425],"vivo":[130,279],"models.":[131],"Methods:":[132],"model":[134,151],"tumor":[135,148,483],"cells":[136,160,172,231,241,264,320,334,355,366,373,382,392,405,458,490,510],"that":[137,187,454],"have":[138],"lost":[139],"A2":[140,163,191,417,529],"via":[141,244],"LOH,":[142],"used":[144],"CD19+":[145,158,185],"Raji":[146,159,272,285,288,324,328,351,354,372,397,412],"corresponding":[153],"\"normal\"":[154,481],"established":[157,294],"stably":[161],"expressing":[162],"(CD19+/A2+":[164],"Raji).":[165,193],"then":[167],"engineered":[168,233,307],"human":[169,308],"primary":[170,195,227,309,316,362],"express":[174,190],"modular":[176],"signal-integration":[177],"circuit":[178],"designed":[179],"be":[181],"activated":[182],"only":[183,369],"do":[188,459],"not":[189,394,460],"(CD19+/A2-":[192],"Each":[194],"Tmod":[196,228,261,310,317,331,363,379,389,402,433,455,487,507],"expresses":[200],"CD19":[203],"activator":[204],"(A)":[205],"CD19-targeting":[209,401],"3rd":[210],"generation":[211],"CAR,":[212],"separate":[215],"A2-targeting":[216,223],"blocker":[217],"(B)":[218],"inhibitory":[224],"receptor.":[225],"Human":[226],"were":[232,242,265,291,359],"co-express":[235],"A/B":[237,249],"modules.":[238],"First,":[239],"stimulated":[243],"CD3/CD28":[245],"activation,":[246],"followed":[247],"lentivirus":[251],"transduction,":[252],"enriched":[254],"for":[255,267,432,504],"module.":[258],"In":[259,377],"selective":[268,409],"killing":[269],"CD19+/A2-":[271,284,323,350,371,385],"compared":[273],"CD19+/A2+":[275,287,327,353,396],"Raji.":[276,386],"For":[277],"proof":[280],"concept,":[282],"lines":[290],"injected":[292],"into":[295,463],"flanks":[296],"immunocompromised":[298],"NGS":[299],"mice":[300],"challenged":[302],"adoptive":[304],"transfer":[305],"Results:":[314],"Engineered":[315],"selectively":[321,367,383,492],"killed":[322],"spared":[326],"(Figure":[329],"1).":[330],"reversibly":[335],"cycled":[336],"state":[339,465],"non-killing,":[341],"\"block\",":[342],"cytotoxicity":[344],"back,":[346],"depending":[347],"on":[348,738],"vs.":[352],"which":[357],"they":[358,477],"exposed.":[360],"Importantly,":[361],"eliminated":[368],"mixed":[375],"cultures.":[376],"vivo,":[378],"eradicated":[384],"More":[387],"importantly,":[388],"did":[393],"eradicate":[395],"vivo.":[399,428],"Conclusions:":[400],"demonstrated":[406],"robust":[407],"killing,":[410],"distinguishing":[411],"lines,":[414],"one":[415,420,464],"(CD19+/A2+)":[418],"without":[421],"(CD19+/A2-),":[422],"A":[429],"critical":[430],"requirement":[431],"determine":[439],"reversibility":[440],"lack":[442],"anergy":[444],"kill-\"block\"-kill":[447],"\"block\"-kill-\"block\"":[449],"scenarios.":[450],"This":[451],"result":[452],"demonstrates":[453],"terminally":[461],"differentiate":[462],"(blockade":[466],"or":[467,619,698,719,744],"activation),":[468],"but":[469],"rather":[470],"can":[471,491],"switch":[472],"back":[473],"forth":[475],"as":[476],"integrate":[478],"signals":[479],"Furthermore,":[485],"because":[486],"malignant":[494],"may":[498,511],"increase":[499],"therapeutic":[502],"window":[503],"T.":[506],"provide":[512],"address":[517],"hematologic":[518],"malignancies":[519],"solid":[521],"Disclosures":[527],"Hamburger:":[528],"Biotherapeutics:":[530,540,544,554,564,568,578,588,598,628,638,676,728],"Employment,":[532,546,556,570,580,590,600,630,678,730],"equity":[534,548,558,572,582,592,602,609,615,632,641,680,687,694,708,715,732],"holder":[535,549,559,573,583,593,603,610,633,642,681,688,709,733],"private":[537,551,561,575,585,595,605,618,635,683,697,718,735],"company.":[538,552,562,576,586,596,636],"DiAndreth:A2":[539],"Employment.":[542,566],"Daris:A2":[543],"Munguia:A2":[553],"Deshmukh:A2":[563],"Mock:A2":[567],"Asuelime:A2":[577],"Lim:A2":[587],"Kreke:A2":[597],"company;":[606,684,691,712],"Gilead:":[607,706],"publicly-traded":[612,620,644,690,699,711,720],"company,":[613,645,736],"Divested":[614,693,714],"company":[621,700,721],"past":[624,703,724],"24":[625,704,725],"months.":[626,726],"Tokatlian:A2":[627],"Maloney:A2":[637],"Consultancy,":[639,649,652,657,661,664,668],"Honoraria;":[646,650,658,662,665],"Bioline":[647],"Rx:":[648],"Celgene:":[651],"Honoraria,":[653,669],"Research":[654,673,750],"Funding;":[655],"Genentech:":[656],"Gilead":[659],"Science:":[660],"Amgen:":[663,685],"Juno":[666],"Therapeutics:":[667],"Patents":[670,747],"&":[671,748],"Royalties,":[672,749],"Funding.":[674,751],"Go:A2":[675],"Allogene:":[692],"months;":[705],"Illumina:":[713],"Kamb:A2":[727],"Membership":[737],"entity's":[740],"Board":[741],"Directors":[743],"advisory":[745],"committees,":[746]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2020-11-09T00:00:00"}